Recercat. Dipósit de la Recerca de Catalunya
Publicación
Artículo científico (JournalArticle)
The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models
Inhibidor de KIF11; Terapias dirigidas; Metástasis, Inhibidor de KIF11; Teràpies dirigides; Metàstasi, KIF11 inhibitor; Targeted therapies; Metastasis, In summary, our study provides a rationale for the future
therapeutic integration in clinical trials of 4SC-205, an
structurally distinct oral KIF11 inhibitor that shows potent
antitumor activity in multiple preclinical neuroblastoma
models and sensitizes neuroblastoma cells to standard
chemotherapy and specific neuroblastoma-targeted therapies., The financial support for this research was provided by Instituto de Salud Calos III (PI20/00530 to Miguel F. Segura; PI20/01107 to Rosa Noguera; PI17/02248 and CPII18/00027 to Anna Santamaria; PI19/01320 to Alberto Villanueva); Ministerio de Educación, Cultura y Deporte (Grant no. FPU16/01099 to Marc Masanas). This work was also supported by the Asociación NEN (Nico contra el cancer infantil 2017–PVR00157).